<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）预计将在 2026 年 5 月 8 日星期五市场开盘前发布其 2026 年第一季度财报。分析师预计该公司本季度每股收益为（$0.18）。投资者可以查看该公司即将发布的 2026 年第一季度财报摘要页面，以获取关于定于 2026 年 5 月 8 日下午 4:00（东部时间）的电话会议的最新详情。</p>
<p>获取 <strong>MAIA Biotechnology</strong> 的提醒：</p>
<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）最近一次发布季度财报是在 3 月 23 日星期一。该公司报告本季度每股收益为（$0.08），超过分析师一致预期的（$0.13），超出幅度为$0.05。</p>
<h2>MAIA Biotechnology 股票表现</h2>
<p>NYSEAMERICAN MAIA 在星期五的开盘价为$1.33。MAIA Biotechnology 的 52 周最低价为$0.87，52 周最高价为$3.19。该股票的市值为 8069 万美元，市盈率为-1.93，贝塔值为 0.30。该股票的 50 日移动平均价为$1.51，200 日移动平均价为$1.52。</p>
<h2>MAIA Biotechnology 的机构交易</h2>
<p>大型投资者最近对该公司的持仓进行了调整。Marshall Wace LLP 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为$29,000。Jane Street Group LLC 在第二季度获得了 MAIA Biotechnology 的新头寸，价值$52,000。最后，Geode Capital Management LLC 在第二季度将其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前拥有该公司 222,183 股股票，价值$400,000，在此期间又购买了 7,746 股。机构投资者持有该公司 5.65% 的股票。</p>
<h2>关于 MAIA Biotechnology</h2>
<p>（获取免费报告）</p>
<p>MAIA Biotechnology, Inc 是一家临床阶段的生物制药公司，开发一种专有平台，用于单克隆抗体与诊断和治疗放射性同位素的特定位点结合。通过利用精确放射化学，该公司旨在增强基于抗体的成像剂和靶向放射治疗的安全性和有效性。其方法旨在通过 PET 成像提供高对比度的肿瘤可视化，以及在肿瘤学适应症中实现集中细胞毒性。</p>
<p>该公司的产品管线包括多个抗体 - 放射性示踪剂候选药物，优化用于检测不同的肿瘤生物标志物，前临床数据表明其靶向特异性和药代动力学优于传统方法。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 MAIA Biotechnology</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 MAIA Biotechnology 吗？</h2>
<p>在考虑 MAIA Biotechnology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 MAIA Biotechnology 并不在名单上。</p>
<p>虽然 MAIA Biotechnology 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MAIA

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

医药突破 ETF - ALPS

<p>MAIA Biotechnology（NYSEAMERICAN:MAIA）将于 5 月 8 日发布 2026 年第一季度财报，分析师预测每股亏损为 0.18 美元。该公司此前报告每股亏损 0.08 美元，超出预期。MAIA 的股票开盘价为 1.33 美元，市值为 8069 万美元。机构投资者持有该股票的 5.65%，最近 Marshall Wace LLP 和 Jane Street Group LLC 进行了增持。MAIA 专注于开发用于癌症治疗和成像的单克隆抗体偶联物</p>

<p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）预计将在 2026 年 5 月 8 日星期五市场开盘前发布其 2026 年第一季度财报。分析师预计该公司本季度每股收益为（$0.18）。投资者可以查看该公司即将发布的 2026 年第一季度财报摘要页面，以获取关于定于 2026 年 5 月 8 日下午 4:00（东部时间）的电话会议的最新详情。</p>
</div><p>Get <strong>MAIA Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MAIA Biotechnology</strong> 的提醒：</p>
</div><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）最近一次发布季度财报是在 3 月 23 日星期一。该公司报告本季度每股收益为（$0.08），超过分析师一致预期的（$0.13），超出幅度为$0.05。</p>
</div><h2>MAIA Biotechnology Stock Performance</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 股票表现</h2>
</div><p>NYSEAMERICAN MAIA opened at $1.33 on Friday. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The stock has a market capitalization of $80.69 million, a P/E ratio of -1.93 and a beta of 0.30. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.52.</p>
<div class="lb-trans"><p>NYSEAMERICAN MAIA 在星期五的开盘价为$1.33。MAIA Biotechnology 的 52 周最低价为$0.87，52 周最高价为$3.19。该股票的市值为 8069 万美元，市盈率为-1.93，贝塔值为 0.30。该股票的 50 日移动平均价为$1.51，200 日移动平均价为$1.52。</p>
</div><h2>Institutional Trading of MAIA Biotechnology</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 的机构交易</h2>
</div><p>Large investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 2nd quarter worth $52,000. Finally, Geode Capital Management LLC raised its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after purchasing an additional 7,746 shares during the period. Institutional investors own 5.65% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。Marshall Wace LLP 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为$29,000。Jane Street Group LLC 在第二季度获得了 MAIA Biotechnology 的新头寸，价值$52,000。最后，Geode Capital Management LLC 在第二季度将其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前拥有该公司 222,183 股股票，价值$400,000，在此期间又购买了 7,746 股。机构投资者持有该公司 5.65% 的股票。</p>
</div><h2>About MAIA Biotechnology</h2>
<div class="lb-trans"><h2>关于 MAIA Biotechnology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc 是一家临床阶段的生物制药公司，开发一种专有平台，用于单克隆抗体与诊断和治疗放射性同位素的特定位点结合。通过利用精确放射化学，该公司旨在增强基于抗体的成像剂和靶向放射治疗的安全性和有效性。其方法旨在通过 PET 成像提供高对比度的肿瘤可视化，以及在肿瘤学适应症中实现集中细胞毒性。</p>
</div><p>The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个抗体 - 放射性示踪剂候选药物，优化用于检测不同的肿瘤生物标志物，前临床数据表明其靶向特异性和药代动力学优于传统方法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MAIA Biotechnology</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MAIA Biotechnology</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSEAMERICAN&amp;Symbol=MAIA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MAIA Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 MAIA Biotechnology 吗？</h2>
</div><p>Before you consider MAIA Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MAIA Biotechnology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 MAIA Biotechnology 并不在名单上。</p>
</div><p>While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MAIA Biotechnology 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

Market Beat

MAIA Biotech

MAIA Biotech（MAIA）预计将在周五发布季度财报